XXXX and efficacy of isolated lung perfusion with @entity136 in a @entity35 model of pulmonary metastases.

@entity137 @entity8178 @entity420 @entity35 @entity136
BACKGROUND: Long-term @entity137 and efficacy of isolated left lung perfusion (ILuP) with @entity136 ( @entity8178 ) were studied in a @entity35 model of metastatic @entity420 . MATERIALS:                 <AbstractText Label=" @entity137 " NlmCategory="RESULTS">Forty @entity35 were randomized into six groups and administered 160 or 320 mg/kg @entity8178 or buffered starch, received either via intravenous injection (i.v.) or via ILuP. Efficacy experiment: @entity35 with unilateral metastases had ILuP with 320 mg/kg @entity8178 (maximally tolerated dose administered by ILuP), while @entity35 with bilateral metastases had an i.v. injection of 160 mg/kg @entity8178 (maximally tolerated dose given by i.v.). RESULTS: @entity137 experiment: After i.v. treatments, all @entity35 receiving 320 mg/kg @entity8178 died within one week, while @entity35 who had received 160 mg/kg @entity8178 had a survival rate of 60%. After ILuP with 160 mg/kg @entity8178 and 320 mg/kg @entity8178 , survival rates were 83% in both groups. A significant increase in collagen deposits was observed for ILuP with 320 mg/kg @entity8178 compared to @entity35 treated i.v. with 160 mg/kg @entity8178 . Efficacy experiment: Median survival of ILuP @entity35 treated with 320 mg/kg (38 +/- 4 days) was significantly longer compared to i.v. @entity35 treated with 160 mg/kg (27 +/- 2 days; p = 0.02). CONCLUSIONS: ILuP with @entity8178 prolongs survival in experimental metastatic @entity420 while no major acute or long term @entity137 is observed.
